Achillion Pharmaceuticals is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from drug discovery to commercialization in its goal of providing better treatments for people with serious diseases. The Company employs a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement factor D inhibitors. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases.

Employee Rating

3.5More
TypePublic
HQNew Haven, US
Founded1998
Size (employees)81 (est)
Websiteachillion.com
Achillion Pharmaceuticals was founded in 1998 and is headquartered in New Haven, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Achillion Pharmaceuticals

Joseph Truitt

Joseph Truitt

President and Chief Executive Officer
Steven Zelenkofske

Steven Zelenkofske

Chief Medical Officer
Mingjun Huang

Mingjun Huang

Senior Vice President, Head of Research
Martha Manning

Martha Manning

Executive Vice President, General Counsel and Secretary
Michael Banks

Michael Banks

Senior Vice President, Pharmaceutical Sciences
Ky Nam-Wortman

Ky Nam-Wortman

Senior Vice President, Head of Human Resources
Show more

Achillion Pharmaceuticals Office Locations

Achillion Pharmaceuticals has an office in New Haven
New Haven, US (HQ)
300 George St
Show all (1)
Report incorrect company information

Achillion Pharmaceuticals Financials and Metrics

Achillion Pharmaceuticals Revenue

Achillion Pharmaceuticals's revenue was reported to be $15 m in FY, 2016 which is a 77.3% decrease from the previous period.
USD

Net income (Q3, 2018)

(15.9m)

EBIT (Q3, 2018)

(17.4m)

Market capitalization (17-Jan-2019)

318.8m

Closing stock price (17-Jan-2019)

2.3

Cash (30-Sep-2018)

36.3m

EV

282.7m
Achillion Pharmaceuticals's current market capitalization is $318.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

66.1m15.0m

Revenue growth, %

(77%)

General and administrative expense

12.7m15.9m24.7m20.7m24.5m

R&D expense

46.7m53.5m56.6m59.2m65.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

711.0k33.8m711.0k33.8m

General and administrative expense

2.7m3.4m3.6m3.7m10.1m4.9m5.4m5.2m4.8m5.6m5.4m4.8m5.3m7.1m4.2m

R&D expense

11.3m12.8m12.2m12.1m19.8m12.0m13.3m14.2m16.7m15.5m18.3m15.6m14.8m11.4m13.1m

Operating expense total

14.1m16.2m15.8m15.8m29.9m16.8m18.7m19.3m21.5m21.1m23.6m20.5m21.8m18.6m17.4m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

33.5m73.7m81.7m77.3m43.5m

Accounts Receivable

223.2m

Inventories

2.5m1.9m2.7m3.5m

Current Assets

124.8m154.9m462.6m382.5m303.9m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(58.9m)(69.0m)(5.0m)(61.7m)(85.2m)

Depreciation and Amortization

399.0k489.0k694.0k955.0k1.1m

Inventories

(104.0k)575.0k(837.0k)(721.0k)

Accounts Payable

315.0k1.8m(2.3m)2.7m(1.6m)
Quarterly
USDY, 2018

EV/EBIT

-16.3 x

EV/CFO

-5.6 x

Financial Leverage

1 x
Show all financial metrics
Report incorrect company information

Achillion Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Achillion Pharmaceuticals News and Updates

Report incorrect company information

Achillion Pharmaceuticals Blogs

Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Trials and Provides Clinical Development Strategy Update

ACH-4471, First Generation Oral factor D Inhibitor - Proof of Concept Validated in both PNH as Monotherapy and in Combination w/C5 Inhibitor  - Proof of Mechanism Validated in C3G, End of Phase 2 Meeting Targeted for 4Q 2019 ACH-5228, Next Generation Oral factor D Inhibitor - Data Demonstrate 3x to

Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018

NEW HAVEN, Conn. , Dec. 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company focused on advancing its orally administered factor D complement inhibitors into late-stage development and commercialization, announced today that the

Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer

NEW HAVEN, Conn. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Anthony S. Gibney to the position of Executive Vice President and Chief Business Officer, effective immediately. Mr.

Achillion Reports Second Quarter 2018 Financial Results

- Global phase 2 clinical programs for ACH-4471 continue to expand in PNH and C3G - - Completed dosing phase 1 clinical study of ACH-5228 and initiated phase 1 study of ACH-5548 - - June 30, 2018 cash position $295.8 million - NEW HAVEN, Conn. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Achillion

Achillion Pharmaceuticals Company Life and Culture

Report incorrect company information

Achillion Pharmaceuticals Frequently Asked Questions

  • When was Achillion Pharmaceuticals founded?

    Achillion Pharmaceuticals was founded in 1998.

  • Who are Achillion Pharmaceuticals key executives?

    Achillion Pharmaceuticals's key executives are Joseph Truitt, Steven Zelenkofske and Mingjun Huang.

  • How many employees does Achillion Pharmaceuticals have?

    Achillion Pharmaceuticals has 81 employees.

  • Who are Achillion Pharmaceuticals competitors?

    Competitors of Achillion Pharmaceuticals include Adaptive Biotechnologies, WaferGen Biosystems and F-star Biotechnology.

  • Where is Achillion Pharmaceuticals headquarters?

    Achillion Pharmaceuticals headquarters is located at 300 George St, New Haven.

  • Where are Achillion Pharmaceuticals offices?

    Achillion Pharmaceuticals has an office in New Haven.

  • How many offices does Achillion Pharmaceuticals have?

    Achillion Pharmaceuticals has 1 office.